



Vivre mieux,
plus longtemps

Docteur Fabrice NESSLANY
Laboratoire de Toxicologie Génétique
Tél. : 33 (0)3 20 87 72 72
Fax : 33 (0)3 20 87 73 10
e-mail : fabrice.nessler@pasteur-lille.fr

Final Study Report

CONFIDENTIAL

**In Vivo Erythrocytes-BASED Pig-A GENE MUTATION ASSAY
(Performed in Mouse Somatic Cells - Two sampling times)
Combined to the
In Vivo MAMMALIAN ALKALINE COMET ASSAY
(Performed in Mouse Circulating Blood Cells - One sampling time)
(Five treatments followed by 3 co-treatments)**

**Study Number
FSR-IPL 160901**

**Study Completion
17 February 2017**

**Test Item
ADN Telomeractives®**

**Study Director
Dr. Sophie SIMAR**

**Sponsor
HBN**

TEST FACILITY

INSTITUT PASTEUR DE LILLE

Genetic Toxicology Laboratory
1, rue du Professeur Calmette - BP. 245
59019 LILLE CEDEX

SPONSOR

HBN

1 rue des pénitents blancs
31010 TOULOUSE

SPONSOR REPRESENTATIVE

Mr. Gérald GOUDET

TABLE OF CONTENTS

STUDY INFORMATION.....	3
GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT AND REPORT AUTHENTICATION.....	4
QUALITY ASSURANCE STATEMENT	6
ARCHIVE STATEMENT	8
SUMMARY.....	9
1 PURPOSE OF THE STUDY.....	14
2 PRINCIPLE.....	14
2.1 <i>In vivo</i> Erythrocytes-Based Pig-A Gene mutation assay	14
2.2 <i>In vivo</i> comet assay	14
3 ANIMALS AND HUSBANDRY.....	15
3.1 Reason for the choice of the reactive system.....	15
3.2 Animals	15
3.3 Husbandry.....	15
4 TEST ITEM AND VEHICLE INFORMATION	15
4.1 Test item	15
4.2 Vehicle	16
4.3 Formulation of the test item	16
5 DETERMINATION OF TEST ITEM CONCENTRATION IN DOSING FORMULATIONS.....	16
6 PRELIMINARY TOXICITY TEST	16
7 TREATMENTS FOR THE DEFINITIVE GENOTOXICITY ASSAYS.....	16
8 <i>IN VIVO</i> ERYTHROCYTES-BASED PIG-A GENE MUTATION ASSAY	18
8.1 Sample preparation.....	18
8.2 Instrument calibration standards.....	19
8.3 Data acquisition.....	19
8.4 Expression of the results and statistical analysis.....	20
8.5 Acceptance criteria for the results.....	20
8.6 Interpretation of the results	20
8.7 Results for the <i>in vivo</i> erythrocytes based Pig-A gene mutation assay.....	21
9 COMET ASSAY	22
9.1 Cell sampling.....	22
9.2 Protocol for the Comet assay.....	22
9.3 Image analysis	22
9.4 Tail parameters	23
9.5 Determination of the cytotoxicity of the test item	23
9.6 Expression of the results and statistical analysis.....	23
9.7 Acceptance criteria for the results.....	23
9.8 Interpretation of the results	24
9.9 Results for the Comet Assay	24
10 DETERMINATION OF SYSTEMIC EXPOSURE.....	25
11 GENERAL COMMENTS	25
12 STUDY PLAN ADHERENCE.....	25
12.1 Deviations.....	25
12.2 Notes	26
13 CONCLUSION	27
14 REFERENCES.....	28
Appendix No. 1: Recapitulative Tables.....	29
Appendix No. 2: Individual results for animal weight.....	36
Appendix No. 3a: Individual results for the Pig-A assay.....	39
Appendix No. 3b: Statistical analysis for the Pig-A assay	50
Appendix No. 3c: Historical data for the Pig-A assay	62
Appendix No. 4a: Individual data for the comet assay	63
Appendix No. 4b: individual data for percentage of DNA in tail.....	65
Appendix No. 4c: Coding slide.....	71
Appendix No. 4d: Non-parametric statistical analysis	72
Appendix No. 5: Certificate of analysis	75
Appendix No. 6: Final Study Plan FSP-IPL 160901	78
Appendix No. 7: Amendment No. 1 to Final Study Plan FSP-IPL 160901	103

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT AND REPORT AUTHENTICATION

The work described in this report was performed according to the agreed study plan and with the Standard Operating Procedures of the test facility, unless otherwise stated, and was conducted in accordance with:

- OECD Principles of Good Laboratory Practice (as revised in 1997), ENV/MC/CHEM(98)17;
- GLP departmental order 14/3/2000 (Official Journal of 23rd March 2000);
- EC Commission Directive 2004/10/EC of 11th February 2004 (Official Journal No. L050);
- Application of the OECD Principles of GLP to Computerised Systems, No. 10 Consensus Document of the Working Group on Good Laboratory Practice, OECD/GD(95)115.

I consider the data generated and reported to be valid and I declare that this report is a true and accurate record of the results obtained.

As described in the Study Plan, the sponsor certifies that the test item to be tested provided by HBN is identical to the test item described in the Final Study Plan.

Note: No Analytical Certificate of the test item was provided.

No data about Composition (or concentration) or Stability in storage conditions was provided. This constitutes a deviation to the Good Laboratory Practices (OECD, 1997: § 6.2, Characterisation).

No control of concentration in dosing formulation was performed. This also constitutes a deviation to the recommendations of the Good Laboratory Practices (OECD, 1997: §6.2, Characterisation).

Nevertheless, taking into account the nature of the test item (*i.e.* plant extract), this deviation was considered only as a minor deviation.

The study was performed at the Toxicology Department of Institut Pasteur de Lille for genotoxicity assays.


The computer applications used to acquire and derive data for this study included Excel[®] and Comet assay IV. These applications have been validated in the laboratory (Conformity certificates F-TOX-INF-025 and 024).

Otherwise, the computer application used to calculate mutation frequencies and percent RET was provided by the Manufacturer (Litron Laboratories Ltd) of the *In Vivo* MutaFlow Kits (*i.e.* kit used for the Pig-A test). This application was not validated in the laboratory.

Submitted by:

Study director

Dr. Sophie SIMAR

17.2.17 
Date Signature

STUDY *In Vivo* ERYTHROCYTES-BASED Pig-A GENE MUTATION ASSAY
(Performed in Mouse somatic cells - Two sampling times)
Combined to the
In Vivo MAMMALIAN ALKALINE COMET ASSAY
(Performed in Mouse Circulating blood cells - One sampling time)
(Five treatments followed by 3 co-treatments)

TEST ITEM ADN Telomeractives®

SPONSOR HBN

This report was reviewed and approved by:

Test Facility Management

Dr. Fabrice NESSLANY
Head of Toxicology Department

16/02/2017

Date



Signature

Deputy Study Director

Mrs. Gwendoline MORDACQ

In Vivo ERYTHROCYTES-BASED Pig-A GENE MUTATION ASSAY
(Performed in Mouse somatic cells - Two sampling times)
Combined to the
In Vivo MAMMALIAN ALKALINE COMET ASSAY
(Performed in Mouse Circulating blood cells - One sampling time)
(Five treatments followed by 3 co-treatments)

SUMMARY

SPONSOR : HBN
TEST ITEM : ADN Telomeractives®
BATCH NUMBER : N002
STUDY LOCATION : INSTITUT PASTEUR DE LILLE
Genetic Toxicology Laboratory
1, rue du Professeur Calmette - B.P. 245
59019 LILLE CEDEX FRANCE

THIS STUDY WAS CARRIED OUT IN COMPLIANCE WITH GOOD LABORATORY PRACTICE REGULATIONS

Study initiation date (date Study Director signed Study Plan):	27/09/2016
<u>Main assay</u>	
Treatments (with the test item alone):	17 to 21/10/2016
Co-treatments (test item +/- ENU)	24 to 26/10/2016
Sampling for Comet assay	26/10/2016
D31/32 sampling for Pig-A	23&24/11/2016
D44 sampling for Pig-A	07/12/2016
Experimental completion date:	21/12/2016
<u>Study completion</u>	17/02/2017

AIM

The evaluation of the protective potential, eg. fight against primary DNA damage and/or optimization of DNA repair capability, of the ADN Telomeractives® test sample was studied using two different endpoints: the measurement of mutant frequency by *in vivo* Erythrocytes-Based Pig-A Gene mutation assay and the evaluation of primary DNA damage by the *in vivo* Comet assay following the alkaline version (pH > 13) in circulating blood cells in mice treated with both the test item and the positive reference substance ethylnitrosourea (ENU).

CONCLUSION

The test item ADN Telomeractives® (batch N002), provided by HBN, was investigated for its protective potential against DNA damaging agent, eg. fight against primary DNA damage and/or optimization of DNA repair capability, by the means of the evaluation of primary DNA damage by in vivo Comet assay following the alkaline version (pH > 13) in circulating blood cells based on OECD Guideline (No. 489, 2014) and the in vivo Erythrocytes-Based Pig-A Gene mutation assay, in male OF1 mice.

Animals were pre-treated with the test item alone at dose levels of 550 and 55 mg/kg. Oral treatments were carried out once a day for 5 consecutive days, 24 hours apart. Then, after 2 days without any treatment, mice were treated thrice, 24-hours apart, with the test item at the 2 same dose levels. One hour after each treatment with the test item, animals were treated with either the DNA damaging agent ethylnitrosourea or its vehicle.

The validity criteria for the results were fulfilled. The study was thus considered as valid.

Under our experimental conditions, ADN Telomeractives® induced no mutagenic activity in circulating blood cells from OF1 male mice. Furthermore, the test item did not present DNA strand breaks and/or alkali-labile sites inducer activities toward the circulating blood cells from male OF1 mice,



On the other hand, under these operating conditions, in vivo, ADN Telomeractives® decreased both DNA fragmentation and mutation frequency induced by ethylnitrosourea, a well-known potent mutagen/carcinogen. Therefore, ADN Telomeractives® is considered to have a protectant potential against primary DNA damage and mutation induced by a strong mutagenic substance ENU.

Figure 1

In Vivo ERYTHROCYTES-BASED Pig-A GENE MUTATION ASSAY
 (Performed in Mouse somatic cells - Two sampling times)
 Combined to the
In Vivo MAMMALIAN ALKALINE COMET ASSAY
 (Performed in Mouse Circulating blood cells - One sampling time)
 (Five treatments followed by 3 co-treatments)

Sponsor: **HBN**
 Test item: **ADN Telomeractives®**
 Vehicle: **CMC at 0.5% in sterile water**

Species: **Mouse**
 Strain: **OF1**
 Route: **oral**
 Volume: **10 mL/kg***



* Phase I: 10 mL/kg/day (x5) - Phase II: 10 mL/kg/day (test item or vehicle control) + 10 mL/kg/day (x3) (ENU or sterile water)